The economic consequences of prostate and bladder cancer in the UK-Reference-Cited by-同舟云学术

The economic consequences of prostate and bladder cancer in the UK

Published:2005-01 Issue:1 Volume:95 Page:59-63
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Sangar Vijay K.,Ragavan Narasimhan,Matanhelia Shyam S.,Watson Mike W.,Blades Rosie A.

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2005.05249.x/fullpdf

Reference18 articles.

1. 1 Office of National Statistics. Series MB1 no. 30. Registration of cancer diagnosed in England. London: Her Majesty's Stationary Office, 1999

2. 2 Office of National Statistics. Series MB1. No. 28. Registrations of Cancer Diagnosed in 1995-97 in England. London: Her Majesty's Stationary Office, 1997

3. 3 Offices for National Statistics. Series DH2. No 23. Mortality Statistics by Cause. England and Wales 1996. London: Her Majesty's Stationary Office, 1996

4. Results of Conservative Management of Clinically Localized Prostate Cancer

5. Rationale for Intensive Intravesical Chemotherapy for Superficial Bladder Cancer

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health literacy in prostate cancer: What do Spanish men know about prostate cancer? A cross-sectional descriptive study;Actas Urológicas Españolas (English Edition);2024-06

2. Alfabetización en salud en cáncer de próstata: ¿qué saben los varones españoles sobre el cáncer de próstata? Estudio descriptivo transversal;Actas Urológicas Españolas;2024-06

3. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer;Molecular Oncology;2024-05-08

4. A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design;Clinical Oncology;2024-01

5. Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial;European Urology Open Science;2023-07